A recent study in a model of metabolic disease identified that a sEH inhibitor enhanced the protective effects identified in Fat-1 mice vs. WT mice (Lopez-Vicario et al., 2015), while previous studies also identify beneficial effects of sEH inhibition in murine models of acute lung injury (Zhou et al., 2017), pulmonary fibrosis (Zhou et al., 2016), asthma (Yang et al., 2015), and COPD (Wang et al., 2012). Here, EPHX2 is linked to asthma.